Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 1Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 109Bevacizumab 97Magnetic Resonance Spectroscopy 91Specimen Handling 88Biopsy 75Paclitaxel 64fludarabine phosphate 62Immunoglobulin G 61Disulfides 61Carboplatin 58Taxes 53Cisplatin 52Doxorubicin 51fludarabine 49Sorafenib 46Radiation 46aldesleukin 45Radiotherapy 45Prednisone 45Etoposide 45Vincristine 41Sirolimus 40Platinum 40Bortezomib 38Rituximab 371,2-diaminocyclohexaneplatinum II citrate 37Nivolumab 36Cytarabine 35temsirolimus 34Vorinostat 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Has results × octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00058214 2015-02-23

Perifosine in Treating Patients With Recurrent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled 5 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡